Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.

Abstract

PURPOSE:

The aim of the present study was to characterize the pharmacokinetics of irinotecan and its four main metabolites (SN-38, SN-38G, APC and NPC) in metastatic colorectal cancer patients treated with FOLFIRI and FOLFIRINOX regimens and to quantify and explain the inter-individual pharmacokinetic variability in this context.

METHODS:

A multicenter study including 109 metastatic colorectal cancer patients treated with FOLFIRI or FOLFIRINOX regimen, associated or not with a monoclonal antibody, was conducted. Concentrations of irinotecan and its four main metabolites were measured in 506 blood samples during the first cycle of treatment. Collected data were analyzed using the population approach. First, fixed and random effects models were selected using statistical and graphical methods; second, the impact of covariates on pharmacokinetic parameters was evaluated to explain the inter-individual variability in pharmacokinetic parameters.

RESULTS:

A seven-compartment model best described the pharmacokinetics of irinotecan and its four main metabolites. First-order rates were assigned to distribution, elimination, and metabolism processes, except for the transformation of irinotecan to NPC which was nonlinear. Addition of a direct conversion of NPC into SN-38 significantly improved the model. Co-administration of oxaliplatin significantly modified the distribution of SN-38.

CONCLUSION:

To our knowledge, the present model is the first to allow a simultaneous description of irinotecan pharmacokinetics and of its four main metabolites. Moreover, a direct conversion of NPC into SN-38 had never been described before in a population pharmacokinetic model of irinotecan. The model will be useful to develop pharmacokinetic-pharmacodynamic models relating SN-38 concentrations to efficacy and digestive toxicities.

CLINICAL TRIALS REGISTRATION NUMBER:

ClinicalTrials.gov identifier: NCT00559676.

• Authors: Laure Deyme, Dominique Barbolosi, Litaty Céphanoée Mbatchi, Nicole Tubiana-Mathieu, Marc Ychou, Alexandre Evrard, Florence Gattacceca
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 88 Issue 2 Pg. 247-258 (08 2021) ISSN: 1432-0843 [Electronic] Germany
• PMID: 33912999 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Topoisomerase I Inhibitors
• folfirinox
• Oxaliplatin
• Irinotecan
• Leucovorin
• Fluorouracil
• Camptothecin

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Camptothecin (analogs & derivatives, therapeutic use)
• Colorectal Neoplasms (drug therapy, metabolism)
• Female
• Fluorouracil (therapeutic use)
• Humans
• Irinotecan (pharmacokinetics, therapeutic use)
• Leucovorin (therapeutic use)
• Male
• Oxaliplatin (therapeutic use)
• Topoisomerase I Inhibitors (pharmacokinetics, therapeutic use)